AzTrials
AzTrials

Non-Alcoholic Fatty Liver DiseaseNCT03942822

Chia Supplementation and Non Alcoholic Fatty Liver Disease

A study testing Milled chia seeds in people with Non-Alcoholic Fatty Liver Disease and Dietary Modification, run by Instituto Nacional de Cardiologia Ignacio Chavez.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Parallel to epidemic obesity, non-alcoholic fatty liver disease (NAFLD) prevalence has markedly increased during the last years, and recent data point out that one of three adults courses with this disease. Read more about this study

Who is it for?
Ages 30 to 70 years
What is being tested?
Milled chia seeds
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
No sites listed yet
Study dates
1 Sep 2016to 1 Sep 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Tomographic diagnosis of NAFLD
  • Insulin resistance (HOMA-IR > 3.7 in women and 3.4 in men)

Who cannot join

  • Previous diabetes diagnosis
  • Use of hypoglycemic or hypolipidemic medications
  • Significant weight changes during the previous 3 months (± 5% of their habitual weight)
  • Consumption of vitamins, herbal or food supplements
  • Gastrointestinal, renal, or hepatic diseases
  • Eating, psychiatric or cognitive disorders that would hinder them of understanding and complying with the instructions of the study.

About this study

Official title: Effect of a Chia Supplemented Diet (Salvia Hispanica) on the Cardiometabolic Risk Profile in Patients With NAFLD (Non Alcoholic Fatty Liver Disease)

Parallel to epidemic obesity, non-alcoholic fatty liver disease (NAFLD) prevalence has markedly increased during the last years, and recent data point out that one of three adults courses with this disease. NAFLD etiopathogeny is multifactorial, an inadequate diet characterized by high fructose content and deficient consumption of omega-3 fatty acids, scarce physical activity, excess abdominal visceral fat (AVF), insulin resistance, and genetic susceptibility have shown to be relevant determinants. Although NAFLD can progress to cirrhosis and hepatic carcinoma, its most frequent complications are type 2 diabetes mellitus (DM2) and coronary artery disease (CAD); therefore, NAFLD is considered a multisystemic disease and a public health problem.

Currently, no specific pharmacological treatment is available for NAFLD, hence, modifications in life style, including weight loss by caloric restriction and increased physical activity, are still the treatment of choice for this type of patients. Recent studies indicate that the supplementation of the diet with omega-3 fatty acids of marine origin (eicosapentanoic acid [EPA]/docosahexaenoic acid [DHA]) and the Mediterranean-style diet (rich in omega-3, antioxidants, and fiber) are efficient for NAFLD treatment, because they diminish the intrahepatic fat content and improve the metabolic profile, even in non-caloric restriction diets. However, the socioeconomic and cultural characteristics make the consumption of these food difficult in some populations, which has led to the search of alternative vegetal sources rich in these nutrients.

Although, there is evidence in animal models suggesting that chia (Salvia hispanica L.) could be an alternative able to reduce the intrahepatic fat content, its effect on NAFLD has not been studied in humans. Hence, the objective of this study was to analyze whether the consumption of an isocaloric diet supplemented with 25 g/day of chia can diminish NAFLD and the metabolic anomalies that accompany the disease.

Read the detailed description

Participants were chosen from the control group of the Genetics of the Atherosclerotic Disease (GEA, for its initials in Spanish) study, performed at the Institute National of Cardiology "Ignacio Chávez" in Mexico City, Mexico. The protocol was approved by the Research and Ethics Committee of the Instituto Nacional de Cardiología "Ignacio Chavez" under the number 16-980. Candidates that accepted to participate in the study signed voluntarily the informed consent.

In order to know eating habits and standardize macronutrient dietary composition, 24-hour dietary recalls will be applied in the first visit, considering two weekdays and one day of the weekend. Patients will be instructed to maintain constant their physical activity throughout the study. To standardize macronutrient dietary composition, an isocaloric diet (55% carbohydrate, 30% fat, and 15% protein diet) will be indicated two weeks before starting chia supplementation. After this, participants will be instructed to keep up this macronutrient composition during all the intervention period. 30 packages of 25 g of chia seeds will be provided to each patient monthly, with the instruction to mill one package per day, pointing out on the relevance of consume the milled chia accompanied by with water, salads, cereal, or other dishes, from breakfast through lunch but always before 6:00 PM. To favor treatment adherence and record adverse events (loss appetite loss, constipation, diarrhea, flatulence and nausea, allergy or chía chia intolerance), patients will be contacted once a week during the intervention. Adherence will be determined by counting empty chia packages, and evaluation of alpha linolenic acid (ALA) concentration in plasma, which is the chia's seeds main fatty acid compound.

Anthropometric evaluation, laboratory test, and computed tomography studies will be made at baseline and after the 8-wk intervention.

Nutritional intervention and food intake evaluation In order to know eating habits and standardize macronutrient dietary composition, 24-hour dietary recalls will be applied in the first visit, considering two weekdays and one day of the weekend. Patients will be instructed to maintain constant their physical activity throughout the study. To standardize macronutrient dietary composition, an isocaloric diet (55% carbohydrate, 30% fat, and 15% protein diet) will be indicated two weeks before starting chia supplementation. After this, participants will be instructed to keep up this macronutrient composition during all the intervention period. 30 packages of 25 g of chia seeds will be provided to each patient monthly, with the instruction to mill one package per day, pointing out on the relevance of consume the milled chia accompained by with water, salads, cereal, or other dishes, from breakfast through lunch but always before 6:00 PM. To favor treatment adherence and record adverse events (loss appetite loss, constipation, diarrhea, flatulence and nausea, allergy or chía chia intolerance), patients will be contacted once a week during the intervention.

Adherence will be determined by counting empty chia packages, and evaluation of alpha linolenic acid (ALA) concentration in plasma, which is the chia's seeds main fatty acid compound. Participants wre excluded when the adherence was lower tan 80% according to the package counting, or when plasma ALA concentration increased less than 30%.

Anthropometric evaluation, laboratory test, and computed tomography studies will be made at baseline and after the 8-wk of diet intervention.

Anthropometric evaluation: Weight and height will be recorded using a calibrated scale and wall stadiometer, with an accuracy of 0.1 Kg kg and 0.1 cm, after removing excess clothing and shoes. The body mass index (BMI) was calculated as weight (kg)/height (m2). Waist circumference will be measured with a non-stretch tape, at the midway between the lowest rib and the iliac crest without clothes around the waist.

Laboratory tests: After 10-h fasting and 20 min in sitting position, venous blood will be collected in assay tubes without anticoagulant and in tubes with K2-EDTA (1.8 mg/mL). Glucose, total cholesterol, triglyceride, and high density lipoprotein cholesterol (HDL-C) concentrations will be determined using direct standard enzymatic colorimetric methods on a COBAS c311 (Roche Diagnostics, Mannheim, Germany). Low density lipoprotein cholesterol (LDL-C) concentration was estimated using the De Long formula. The reproducibility and precision of these determinations in our laboratory is assessed by the Center for Disease Control and Prevention Lipids Standardization Program (LSP-CDC, Atlanta, GA, USA). Plasma free fatty acids (FFA) will be measured by an enzymatic-colorimetric assay (Wako Diagnostics, Chuo-Ku Osaka, Japan). Total fatty acids, including ALA will be extracted according to Folch method, and analyzed in a Shimadzu GC-8A gas chromatograph equipped with an SP2330 capilar column (25m x 0.25 mm x 0.25). Fatty-acid concentrations will be calculated in relation to heptadecanoic acid methyl ester as internal standard, fatty acids peaks will be identified by using the Supelco 37 component FAME Mix (CRM47885). A plasma control sample will be run in each extraction assay, to obtain an ALA inter-assay coefficient variation.

Computed tomography study: Computed tomography (CT) is a validated method for measuring visceral adipose tissue (VAT) and evaluate non alcoholic fatty liver disease. In the present study, these measurements will be obtained using a 64-slice scanner (Somatom Cardiac Sensation 64, Forcheim, Bavaria, Germany). To determine the liver and spleen attenuation index, a single slice CT scan is obtained at the level of T11-T12 or T12-L1. Fatty liver is defined as a liver/spleen attenuation ratio lower than 1.0. To calculate the amount of total abdominal tissue (TAT) and VAT, a single slice scan is obtained at the level of L4-L5, the area is expressed in square centimeters (cm2). Subcutaneous abdominal tissue (SAT) was calculated by subtracting the VAT from the TAT area.

Being tested
Milled chia seeds
Keywords
Non-Alcoholic Fatty Liver Disease, Milled chia seed suplementation
Medical subject headings
Non-alcoholic Fatty Liver Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Milled chia seedsDietary supplement

    8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia

Study groups in NCT03942822
Study groupRoleWhat they receive
Chia supplemented groupExperimental8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
Receives: Dietary Supplement: Milled chia seeds

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of a chia (Salvia hispanica L.) supplemented diet in patients with non-alcoholic fatty liver

    To assess the effect of 25 g/day of milled chia in 25 patients with NAFLD.Improvement of LSAI (liver spleen attenuation index) measured by computed tomography In a single-arm experimental design study

    Measured: 8 weeks

  2. Effect of chia on plasma levels of alpha linolenic acid

    Increase in Alpha linolenic acid with chia supplemented diet. Measured by gas chromatography.

    Measured: 8 weeks

Secondary outcomes (1)
  1. Effect of chia on lipid parameters

    Improvement of lipid parameters (total colesterol, LDL-C, triglycerides, HDL-C) including free fatty acids

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2019
  2. Study start1 Sep 2016
  3. Primary completion1 Sep 2017
  4. Study completion1 Sep 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03942822
Sponsor's protocol ID
16-980
Status last verified
May 2019
First submitted
25 Apr 2019
Last updated
8 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Medina-Urrutia A, Lopez-Uribe AR, El Hafidi M, Gonzalez-Salazar MDC, Posadas-Sanchez R, Jorge-Galarza E, Del Valle-Mondragon L, Juarez-Rojas JG. Chia (Salvia hispanica)-supplemented diet ameliorates non-alcoholic fatty liver disease and its metabolic abnormalities in humans. Lipids Health Dis. 2020 May 19;19(1):96. doi: 10.1186/s12944-020-01283-x.

    PubMed 32430018

Questions about this trial

What is this clinical trial studying?

A study testing Milled chia seeds in people with Non-Alcoholic Fatty Liver Disease and Dietary Modification, run by Instituto Nacional de Cardiologia Ignacio Chavez.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 May 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of a chia (Salvia hispanica L.) supplemented diet in patients with non-alcoholic fatty liver (time frame: 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03942822, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in